UNSPSC 51272204: Esketamine or ketamine or (s)-ketamine

This classification denotes an anesthetic agent with the molecular formula C13H16ClNO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 690G0D6V8H, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but more generally known as ketamine, which bears U.S. National Institutes of Health Compound Identifier 3821. The European Medicines Agency schedules Ketamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08365MIG.

UNSPSC 51272204 Esketamine or ketamine or (s)-ketamine is a Commodity code that covers pharmaceutical products for state and local health and human services procurement, though recent solicitations tagged to this code show minimal direct activity in esketamine or ketamine itself. State and local government procurement under this nominal code frame spans pharmaceutical supply agreements, including generic multi-source drugs and over-the-counter products distributed through authorized wholesalers and pharmacy benefit networks, as well as health-related supplies such as naloxone and drug deactivation systems procured by county health departments. Issuing bodies include state health and human services commissions, county health departments, and state-administered cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent state-level actors soliciting pharmaceutical products and services; Seminole County, Florida solicits naloxone and drug deactivation systems for community health delivery.

Geographic activity centers on Minnesota (through MMCAP's multi-state cooperative purchasing platform serving participating states including Oregon), Texas (through the Health and Human Services Commission), and Florida (Seminole County). Recent representative solicitations include MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers with pricing competitiveness weighted at 75 percent and contract effectiveness set for July 1, 2026; Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026, with a bid response deadline of July 26, 2023, requiring quarterly deliveries and fixed-fee pricing; and the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities, posted April 3, 2026, seeking vendor information on direct contracting models outside traditional pharmacy benefit manager arrangements. The code shows limited recent activity directly tied to esketamine or ketamine procurement.